title: [Photodynamic therapy with visudine in combination with intravitreal kenalog in the treatment of choroidal neovascularization].
abstract: There are current tendencies in the use of photodynamic therapy (PDT) in combination with intravitreal injection of long-acting corticosteroids. Kenalog was intavitreally injected in patients with abnormal myopia (4 eyes), multifocal choroiditis (3 eyes), and age-related macular degeneration (6 eyes), and idiopathic choroidal neovascularization (CNV) (1 eye) 10-14 days before PDT. All the above cases were characterized by a severe clinical course with significantly diminished visual function, and evident exudative-hemorrhagic manifestations. A 2-5-line vision increase and bleeding resorption were observed in the patients 1-2 months after PDT. The results of optical coherent tomography suggest a significant reduction or disappearance of exudative manifestations (retinal edema, detachments of the neuroepithelium or pigment epithelium). Fluorescence angiography revealed decreased or ceased dye diffusion in the CNV areas at the late stages of the study. The findings suggest the efficiency of combined therapy for CNV that can improve visual prognosis significantly in patients after PDT.
authors.forename: V V
authors.initials: VV
authors.lastname: Neroev
authors.forename: M V
authors.initials: MV
authors.lastname: Riabina
authors.forename: K R
authors.initials: KR
authors.lastname: Chikovani
authors.forename: N V
authors.initials: NV
authors.lastname: Neroeva
mesh_terms: D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007267:Injections; D033401:Microscopy, Acoustic; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000627:therapeutic use; D000077362:Verteporfin; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D014222:Triamcinolone Acetonide